Our study suggested that HDAC inhibitor and PI3k inhibitor decrease the proliferation of tamoxifen-resistant breast cancer through inhibition of the PI3k/Akt/mTOR signaling pathway. The gene discussed is HDAC9; the disease is breast carcinoma.